Skip to main content
Caplight Logo









Innorna

Innorna

Private
ShenzhenHealthcare & Life Scienceshttps://innorna.com/

Last Round

Series B

Mar 28, 2022

Total Funding Raised

$120M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Innorna is a biotechnology company that develops mRNA-based medicines and proprietary lipid nanoparticle (LNP) delivery systems to treat chronic diseases, power in vivo immunotherapies, and prevent infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

mRNA therapyLNP delivery platformclinical stage biotechmRNA vaccinebiopharma partnershipRNA deliverycGMP manufacturingdrug discovery platformionizable lipidsplatform licensingCMC servicesimmunotherapybiotech CDMOchemistry, manufacturing, and controls

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innorna Comparables

Compare Innorna with similar companies based on industry and business-model similarity.

Innorna comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Immorna Biotherapeutics
89%
Immorna
88%
RVAC Medicines
88%

Innorna Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 28, 2022
Series AJul 22, 2021
AngelNov 1, 2020

Innorna Investors

Notable investors and investment history

Innorna investors
InvestorRounds
Optimas CapitalSeries B
Huasheng CapitalSeries B
Legend CapitalSeries A
CITIC Private Equity Funds ManagementSeries B
YF CapitalSeries B
Fangyuan Capital (Hong Kong) LimitedSeries B
CAS StarSeries A, Angel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 137% MoM, reaching 1K.

  • Jul 13, 2026

    Open roles increased to 7, 58% of headcount.

Innorna Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Innorna Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Innorna's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range12
Year Founded2019
Last FundingMar 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?